跳至主要内容
临床试验/ISRCTN72781592
ISRCTN72781592已完成不适用

Short versus long buprenorphine-naloxone treatment in intravenous buprenorphine withdrawal: a randomised controlled trial

Helsinki Deaconess Institute (Finland)0 个研究点目标入组 120 人开始时间: 2008年3月4日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Opiate dependence (Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition [DSM IV])
  • 2. Current misuse of buprenorphine intravenously (mimimun 3 mg/day) (use confirmed by urinalysis)
  • 3. Willingness to participate in withdrawal in the treatment centre and in rehabilitation afterwards
  • 4. Aged between 18 and 50

排除标准

  • 1. Other than buprenorphine as the primary drug of misuse
  • 2. Misuse of other opiates then buprenorphine during the last week (confirmed by urinalysis)
  • 3. Opiate maintenance therapy
  • 4. Psychotic symptoms at recruitment
  • 5. Psychiatric or somatic disease or symptoms that may require hospitalisation at near future
  • 6. Salient increase in alanine aminotransferase (ALAT)
  • 7. Pregnancy
  • 8. Allergy to lofexidine, buprenorphine or naloxone
  • 9. Former participation to the same study
  • 10. Concurrent participation to other intervention studies
  • 11. Native language other than Finnish

研究者

发起方
Helsinki Deaconess Institute (Finland)

相似试验

Short versus long buprenorphine-naloxone treatment... | 临床试验